Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 12/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 12/20 | 0.52 |
| ▸ | RAB9A | P51151 | 9/20 | 0.52 |
| ▸ | NPC1 | O15118 | 8/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | VCP | P55072 | 1/20 | 0.49 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL206223 | 0.89 | MEN1 (0.53) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL3131847 | 0.83 | CCNA2 (0.39) | MEN1KMT2ARAB9AMAPTSMN1; SMN2 | |
| SCHEMBL3128105 | 0.83 | MEN1 (0.58) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL205028 | 0.82 | MEN1 (0.68) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL205766 | 0.81 | MEN1 (0.53) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL2755821 | 0.81 | MEN1 (0.67) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL206654 | 0.80 | MEN1 (0.56) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL207200 | 0.80 | MEN1 (0.57) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL206964 | 0.79 | MEN1 (0.50) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL205592 | 0.79 | P2RX3 (0.42) | MEN1KMT2ARAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183263-B2 | Heteroaryl substituted thiazoles | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-22 | — | — | US | claimed |
| EP-2164846-A2 | HETEROARYL SUBSTITUTED THIAZOLES AND THEIR USE AS ANTIVIRAL AGENTS. | Achillion Pharmaceuticals, Inc. (US) | 2010-03-24 | — | — | EP | claimed |
| US-20090041720-A1 | HETEROARYL SUBSTITUTED THIAZOLES | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | US | claimed |
| WO-2008147557-A2 | HETEROARYL SUBSTITUTED THIAZOLES AND THEIR USE AS ANTIVIRAL AGENTS | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | WO | claimed |
| US-8183263-B2 | Heteroaryl substituted thiazoles | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183263-B2 | Heteroaryl substituted thiazoles | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183263-B2 | Heteroaryl substituted thiazoles | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090041720-A1 | HETEROARYL SUBSTITUTED THIAZOLES | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090041720-A1 | HETEROARYL SUBSTITUTED THIAZOLES | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090041720-A1 | HETEROARYL SUBSTITUTED THIAZOLES | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041720-A1 | HETEROARYL SUBSTITUTED THIAZOLES | CYP3A43, CYP3A7, HAVCR2 | MEN1 2144/4885KMT2A 3706/4885RAB9A 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.